Does pharmacokinetic variability influence the efficacy of high-dose methotrexate for the treatment of children with acute lymphoblastic leukemia: what can we learn from small studies?
Evans
W E
WE
Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN 38101, USA.
Relling
M V
MV
Boyett
J M
JM
Pui
C H
CH
D000964:Antimetabolites, Antineoplastic / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002648:Child; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008727:Methotrexate / Q000493:pharmacokinetics* / Q000627:therapeutic use; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood / Q000188:drug therapy*; D011379:Prognosis; D012008:Recurrence; D018570:Risk Assessment
D000964:Antimetabolites, Antineoplastic; D008727:Methotrexate